Study details
Enrolling now
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
University of Washington
NCT IDNCT05822609ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
60
Study length
about 2.2 years
Ages
18+
Locations
3 sites in CO, WA
About this study
Researchers are testing whether semaglutide helps with kidney health and function in people with type 1 diabetes. The trial also looks at how semaglutide affects blood sugar levels and safety in this population.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Semaglutide
PhasePhase 2
DrugSemaglutide
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
semaglutide (GLP-1 agonist; stimulates insulin release)
Drug routes
oral (Oral Tablet)
Endpoints
Secondary: Change in estimated glomerular filtration rate
Body systems
Endocrinology, Renal